Study Name: Novel Mechanisms Underlying Depression: PET Imaging of the Kappa Opioid Receptor
Principal Investigator: Jeffrey M. Miller, M.D.
Purpose of Study: The purpose of this study is to look at a protein in the brain, called the kappa opioid receptor (KOR), to see if its levels are different in people suffering from depression. A receptor is a protein in the brain that affects brain function. The long-term goal of this study is to help us understand the causes of depression better, and eventually to suggest new types of treatments for depression. We will be comparing brain scans from this study between individuals suffering from depression and volunteers without depression.
Treatment Offered: This study provides up to 6 months of medication-based treatment of depression by a study psychiatrist at the MIND outpatient clinic. You may also choose inpatient treatment at the New York State Psychiatric Institute where you may receive a combination of medication and psychotherapy. If you are interested in psychotherapeutic treatment for your depression, you may be eligible to enroll simultaneously in "Predictors of Treatment Outcome with Cognitive Behavioral Therapy for Depression," (Principal Investigator: Jeffrey Miller, MD), in which you would receive 12 weeks of psychotherapy.
Eligibility: You must be 21-55 years old. Depressed participants must meet criteria for Major Depressive Disorder (MDD). We are also recruiting volunteers without depression to participate in this study, who will complete brain imaging, but will not receive antidepressant treatment. You must be willing to travel to the Yale PET Center in New Haven, CT.
Funding: National Institutes of Health (NIH) through Columbia University
Website: Depression Study Web Site